S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Sprinklr Gets Targets Raised By Analysts, Here's Why
Time To Buy Uranium? Cameco Is The Top Pick
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Sprinklr Gets Targets Raised By Analysts, Here's Why
Time To Buy Uranium? Cameco Is The Top Pick
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Sprinklr Gets Targets Raised By Analysts, Here's Why
Time To Buy Uranium? Cameco Is The Top Pick
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
Stock market today: Asian shares slip following technology selloff on Wall Street
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Tesla: How and Why It Gets To $300
Don't Overlook Hidden Gem Kinsale As Rallies To New Highs
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
AI-powered IoT Automation is Driving Samsara To New Highs
What is a Growth Stock Mutual Fund?
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
Sprinklr Gets Targets Raised By Analysts, Here's Why
Time To Buy Uranium? Cameco Is The Top Pick
TSE:ATE

Antibe Therapeutics (ATE) Stock Forecast, Price & News

C$0.50
-0.01 (-1.96%)
(As of 06/7/2023 ET)
Compare
Today's Range
C$0.50
C$0.50
50-Day Range
C$0.49
C$0.60
52-Week Range
C$0.41
C$0.71
Volume
13,000 shs
Average Volume
30,500 shs
Market Capitalization
C$26.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ATE stock logo

About Antibe Therapeutics (TSE:ATE) Stock

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. Its lead compound is Otenaproxesul, a hydrogen sulfide-releasing derivative of naproxen for treating post-operative pain, migraine, dysmenorrhea, traumatic injury, dental pain, and gout that has completed Phase 2B gastrointestinal safety study. In addition, the company's products comprise ATB-352, which is in preclinical stage for acute pain. Antibe Therapeutics Inc. was incorporated in 2009 and is headquartered in Toronto, Canada.

Receive ATE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Antibe Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATE Stock News Headlines

Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
Closing Bell: Antibe Therapeutics Inc up on Tuesday (ATE)
Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
Antibe Provides April 2023 Corporate Update
Antibe Therapeutics Inc stock advanced on Friday.
Antibe Therapeutics Announces Amendment to Warrant Terms
Antibe Therapeutics Inc. (ATE.TO)
See More Headlines

ATE Price History

ATE Company Calendar

Today
6/07/2023
Next Earnings (Estimated)
7/05/2023

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
47
Year Founded
N/A

Profitability

Net Income
C$-21,340,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$9.71 million
Cash Flow
C$0.82 per share
Book Value
C$0.82 per share

Miscellaneous

Free Float
N/A
Market Cap
C$26.24 million
Optionable
Not Optionable
Beta
0.17

Key Executives

  • Mr. Daniel Marcel Legault J.D. (Age 65)
    L.L.B., Pres, CEO, Sec. & Director
    Comp: $638.26k
  • Dr. John Lawrence Wallace M.B.A. (Age 66)
    M.Sc., MBA, MSc, Ph.D., Founder & Vice Chair
    Comp: $638.26k
  • Mr. Alain Wilson M.B.A.
    MBA, Chief Financial Officer
  • Mr. Scott Curtis C.F.A.
    M.Eng, Chief Operating Officer
  • Dr. David James Vaughan Ph.D. (Age 73)
    Chief Devel. Officer
    Comp: $375.53k
  • Dr. Joseph Stauffer D.O. (Age 57)
    M.B.A., Chief Medical Officer
    Comp: $735k
  • Dr. Ana Stegic
    Director of Clinical Operations
  • Ms. Christina Cameron B.B.A.
    VP of Investor Relations
  • Mr. Philip Stern
    VP of Communications













ATE Stock - Frequently Asked Questions

Should I buy or sell Antibe Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Antibe Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATE shares.
View ATE analyst ratings
or view top-rated stocks.

How have ATE shares performed in 2023?

Antibe Therapeutics' stock was trading at C$0.47 at the start of the year. Since then, ATE stock has increased by 6.4% and is now trading at C$0.50.
View the best growth stocks for 2023 here
.

When is Antibe Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 5th 2023.
View our ATE earnings forecast
.

Is Antibe Therapeutics a good dividend stock?

Antibe Therapeutics (TSE:ATE) pays an annual dividend of C$0.05 per share and currently has a dividend yield of 0.00%.

What is Antibe Therapeutics' stock symbol?

Antibe Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ATE."

How do I buy shares of Antibe Therapeutics?

Shares of ATE stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Antibe Therapeutics' stock price today?

One share of ATE stock can currently be purchased for approximately C$0.50.

How much money does Antibe Therapeutics make?

Antibe Therapeutics (TSE:ATE) has a market capitalization of C$26.24 million and generates C$9.71 million in revenue each year. The company earns C$-21,340,000.00 in net income (profit) each year or C($0.43) on an earnings per share basis.

How can I contact Antibe Therapeutics?

Antibe Therapeutics' mailing address is 15 Prince Arthur Ave, TORONTO, ON M5R 1B2, Canada. The official website for the company is www.antibethera.com. The company can be reached via phone at +1-905-5705103.

This page (TSE:ATE) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -